Products Vorinostat
Vorinostat Phase 1/2 Completed ⚡ Active Feb 1, 2011 → Mar 31, 2016
About Vorinostat Vorinostat is a phase 1/2 stage product being developed by Merck for HIV-1 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01319383. Target conditions include HIV-1 Infection.
Clinical Trials (17) NCT ID Phase Status Start Completion Indication NCT01365065 Phase 2 UNKNOWN May 1, 2011 Jan 1, 2018 HIV Positive NCT01319383 Phase 1/2 Completed Feb 1, 2011 Mar 31, 2016 HIV-1 Infection NCT00918489 Phase 2 Completed May 1, 2010 Sep 1, 2013 Soft Tissue Sarcoma NCT01000155 Phase 2 Terminated Oct 1, 2009 Oct 1, 2014 Sickle Cell Disease NCT00821951 Phase 1 Completed May 1, 2009 Jul 1, 2012 Non-Small Cell Lung Cancer (NSCLC) NCT00831493 Phase 1/2 Terminated May 1, 2009 Oct 1, 2010 Pancreatic Cancer NCT00875056 Phase 2 Completed Apr 15, 2009 Feb 8, 2019 Lymphoma NCT00735826 Pre-clinical Completed Mar 1, 2009 Jul 1, 2012 Aerodigestive Tract Cancer NCT00838929 Phase 1 Completed Mar 1, 2009 Mar 1, 2015 Brain Metastases NCT00719875 Phase 1 Completed Dec 1, 2008 Jun 1, 2013 Advanced Breast Cancer NCT00771472 Phase 1 Completed Aug 1, 2008 Jul 1, 2011 Lymphoma NCT00776503 Phase 1/2 Completed May 1, 2008 Nov 1, 2011 Myelodysplastic Syndromes NCT00561418 Phase 1 Completed Nov 1, 2007 May 1, 2013 Lymphoma NCT00416130 Phase 1/2 UNKNOWN Jan 1, 2007 Jan 1, 2015 Breast Cancer NCT00907738 Phase 2 Completed Aug 1, 2005 Jun 1, 2010 Advanced Cancer NCT00127127 Phase 1 Completed Jun 10, 2005 Aug 21, 2009 Tumors NCT00127140 Phase 1 Completed Jun 1, 2005 Apr 1, 2012 Lymphoma
Product Company Stage Hype Score DOR/ISL Merck Phase 2 SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo Jiangsu Hengrui Medicine Phase 1 Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available AbbVie Approved lopinavir/ritonavir + lamivudine AbbVie Pre-clinical CVC 150 mg + CVC 300 mg AbbVie Phase 2 Doravirine, Tenofovir, Lamivudine - Blinded + Doravirine, Tenofovir, Lamivudine - Open-Label + ATRIPLA^TM + Placebo to ATRIPLA™ + Placebo to Doravirine, Tenofovir, Lamivudine Merck Phase 2 DOR/ISL + BIC/FTC/TAF + Placebo to BIC/FTC/TAF + Placebo to DOR/ISL Merck Phase 3 Islatravir Merck Phase 1 Doravirine, Tenofovir, Lamivudine + Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor + Baseline regimen of cobicistat-boosted elvitegravir + Baseline regimen of a non-nucleoside reverse transcriptase inhibitor + Baseline regimen of two nucleoside reverse transcriptase inhibitors Merck Phase 3 raltegravir and etravirine Merck Phase 2 Treatment A: Doravirine 100 mg film coated tablet + Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) + Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) + Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) + Treatment E: Doravirine 100 mg tablet (30% drug loaded granule) Merck Phase 1 ISL + ULO + BIC/FTC/TAF Merck Phase 2 Ulonivirine Merck Phase 1 Islatravir + Placebo to Islatravir + Doravirine + Placebo to Doravirine + Lamivudine + Placebo to Lamivudine + Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Doravirine/Islatravir Merck Phase 2 MK0518 (Raltegravir) + famotidine + omeprazole Merck Phase 1 Doravirine Merck Phase 1 MK-8510 Merck Phase 1 18F-Raltegravir Merck Phase 1 Pegylated Interferon alpha 2b Merck Phase 2 MK-8583 Merck Phase 1
Other Products from Merck